Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials.
Saved in:
| Title: | Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. |
|---|---|
| Authors: | Francoeur AA; Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA., Liang SY; Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA., File B; Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA., Choi E; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA., Brameld M; Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA., Richardson MT; Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA, USA., Johnson CR; Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, CA, USA., Kapp DS; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA., Tewari KS; Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA, USA., Chan JK; Division of Gynecologic Oncology, California Pacific / Palo Alto / Sutter Health Research Institute, San Francisco, CA, USA. |
| Source: | Gynecologic oncology reports [Gynecol Oncol Rep] 2026 Feb 18; Vol. 64, pp. 102050. Date of Electronic Publication: 2026 Feb 18 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101652231 Publication Model: eCollection Cited Medium: Print ISSN: 2352-5789 (Print) Linking ISSN: 23525789 NLM ISO Abbreviation: Gynecol Oncol Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
